|
WO2008022349A2
(en)
|
2006-08-18 |
2008-02-21 |
Armagen Technologies, Inc. |
Agents for blood-brain barrier delivery
|
|
EP2997976A1
(en)
|
2007-07-27 |
2016-03-23 |
Armagen Technologies, Inc. |
Methods and compositions for increasing alpha-l-iduronidase activity in the cns
|
|
EP2485761B1
(en)
|
2009-10-09 |
2019-02-27 |
Armagen, Inc. |
Methods and compositions for increasing iduronate 2-sulfatase activity in the cns
|
|
AU2012249801B2
(en)
|
2011-04-25 |
2016-05-19 |
Usher Iii Initiative, Inc. |
Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with Usher syndrome
|
|
EP2723746A1
(en)
|
2011-06-22 |
2014-04-30 |
Vertex Pharmaceuticals Inc. |
Compounds useful as inhibitors of atr kinase
|
|
CN107880123A
(zh)
|
2011-10-28 |
2018-04-06 |
普罗典娜生物科学有限公司 |
识别α‑突触核蛋白的人源化抗体
|
|
KR101998818B1
(ko)
|
2011-11-03 |
2019-07-10 |
한민규 |
무선 통신 장치의 장치 식별 정보를 이용한 컨텐츠 표시 방법, 컨텐츠 제공 방법, 상기 컨텐츠 표시 방법을 수행하는 사용자 단말 및 상기 컨텐츠 제공 방법을 수행하는 컨텐츠 제공 시스템
|
|
WO2013086041A1
(en)
*
|
2011-12-05 |
2013-06-13 |
The Trustees Of Columbia University In The City Of New York |
Transcriptome wiring analysis in parkinson's disease and uses thereof
|
|
AU2013211874B2
(en)
|
2012-01-27 |
2017-11-02 |
Prothena Biosciences Limited |
Humanized antibodies that recognize alpha-synuclein
|
|
US8940742B2
(en)
|
2012-04-10 |
2015-01-27 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
|
CA2915127A1
(en)
*
|
2012-06-06 |
2013-12-12 |
Giancarlo PARENTI |
Allosteric chaperones and uses thereof
|
|
JOP20130273B1
(ar)
|
2012-09-11 |
2021-08-17 |
Genzyme Corp |
مثبطات انزيم (سينثاز) غلوكوسيل سيراميد
|
|
UA118441C2
(uk)
|
2012-10-08 |
2019-01-25 |
Протена Біосаєнсиз Лімітед |
Антитіло, що розпізнає альфа-синуклеїн
|
|
US9227976B2
(en)
|
2012-10-25 |
2016-01-05 |
Usher Iii Initiative, Inc. |
Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome
|
|
CN104902923A
(zh)
|
2012-11-05 |
2015-09-09 |
建新公司 |
用于治疗蛋白质病的组合物和方法
|
|
BR112015012454B1
(pt)
|
2012-12-07 |
2022-07-05 |
Vertex Pharmaceuticals Incorporated |
Compostos inibidores de atr quinase, seu uso e composição farmacêutica compreendendo os mesmos
|
|
WO2014143240A1
(en)
|
2013-03-15 |
2014-09-18 |
Vertex Pharmaceuticals Incorporated |
Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase
|
|
WO2014143242A1
(en)
|
2013-03-15 |
2014-09-18 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
|
WO2014143241A1
(en)
|
2013-03-15 |
2014-09-18 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
|
EP3010532A4
(en)
*
|
2013-06-18 |
2017-06-14 |
University of North Carolina at Pembroke |
Materials for positive cathepsin b modulation and methods of use for treating mild cognitive impairment (mci), early dementia, a-synucleinopathy, traumatic brain injury, cardiomyopathy, eye disease and skin damage
|
|
US10513555B2
(en)
|
2013-07-04 |
2019-12-24 |
Prothena Biosciences Limited |
Antibody formulations and methods
|
|
WO2015051244A1
(en)
|
2013-10-04 |
2015-04-09 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
|
US9751888B2
(en)
|
2013-10-04 |
2017-09-05 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
|
ES2768678T3
(es)
|
2013-12-06 |
2020-06-23 |
Vertex Pharma |
Compuesto de 2-amino-6-fluoro-N-[5-fluoro-piridin-3-il]pirazolo[1,5-a]pirimidin-3-carboxamida útil como inhibidor de la ATR quinasa, su preparación, diferentes formas sólidas y derivados radiomarcados de las mismas
|
|
EP3943942A1
(en)
|
2014-02-14 |
2022-01-26 |
betaSENSE GmbH |
Biosensor for conformation and secondary structure analysis
|
|
EP3119397B1
(en)
|
2014-03-19 |
2022-03-09 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
|
|
CA2944402A1
(en)
|
2014-04-08 |
2015-10-15 |
Prothena Biosciences Limited |
Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein
|
|
ES2777608T3
(es)
|
2014-06-05 |
2020-08-05 |
Vertex Pharma |
Derivados radiomarcados de un compuesto de 2-amino-6-fluoro-N-[5-fluoro-piridin-3-il]-pirazolo[1,5-a]pirimidin-3-carboxamida útiles como inhibidores de ATR cinasa, la preparación de dicho compuesto y diferentes formas sólidas del mismo
|
|
KR20170016498A
(ko)
|
2014-06-17 |
2017-02-13 |
버텍스 파마슈티칼스 인코포레이티드 |
Chk1 및 atr 저해제의 병용물을 사용하는 암의 치료 방법
|
|
CN105330579B
(zh)
*
|
2014-08-08 |
2019-08-30 |
杭州雷索药业有限公司 |
依泽替米贝及其衍生物在治疗或预防癫痫中的应用
|
|
WO2016054491A1
(en)
|
2014-10-03 |
2016-04-07 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
|
DK3215511T3
(da)
|
2014-11-06 |
2024-05-13 |
Bial R&D Invest S A |
Substituerede pyrazolo(1,5-a)pyrimidiner og deres anvendelse i behandlingen af medicinske lidelser
|
|
CA2966581A1
(en)
|
2014-11-06 |
2016-05-12 |
Lysosomal Therapeutics Inc. |
Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders
|
|
ES2958391T3
(es)
|
2014-11-06 |
2024-02-08 |
Bial R&D Invest S A |
Imidazo[1,5-a]pirimidinas sustituidas y su uso en el tratamiento de trastornos médicos
|
|
US10441574B2
(en)
|
2014-11-13 |
2019-10-15 |
Washington University |
Treatment for wolfram syndrome and other endoplasmic reticulum stress disorders
|
|
EP3220906B1
(en)
*
|
2014-11-19 |
2022-03-02 |
Rush University Medical Center |
Compositions and methods for treating lysosomal disorders
|
|
TW201642855A
(zh)
*
|
2015-03-10 |
2016-12-16 |
健臻公司 |
用於治療蛋白質病變之方法
|
|
US10016514B2
(en)
*
|
2015-05-15 |
2018-07-10 |
New Hope Research Foundation |
Polynucleotides, vectors and methods for insertion and expression of transgenes
|
|
JP6924155B2
(ja)
|
2015-06-11 |
2021-08-25 |
アッシャー・サード・イニシアティブ・インコーポレイテッド |
プロテオパシーを治療又は予防する方法
|
|
WO2017024204A1
(en)
*
|
2015-08-06 |
2017-02-09 |
Academia Sinica |
Engineered enzyme for enzyme replacement therapy
|
|
WO2017040971A1
(en)
*
|
2015-09-03 |
2017-03-09 |
Biomarin Pharmaceutical Inc. |
Methods of using inhibitors of pikfyve for the treatment of lysosomal storage disorders and neurodegenerative diseases
|
|
CN114230571B
(zh)
|
2015-09-14 |
2025-07-08 |
无限药品股份有限公司 |
异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
|
|
KR102678021B1
(ko)
|
2015-09-30 |
2024-06-26 |
버텍스 파마슈티칼스 인코포레이티드 |
Dna 손상제와 병용되는, atr 저해제를 포함하는 암 치료용 약제학적 조성물
|
|
WO2017123806A1
(en)
|
2016-01-12 |
2017-07-20 |
Cedars-Sinai Medical Center |
A method of non destructive monitoring of biological processes in microfluidic tissue culture systems
|
|
CN105534977A
(zh)
*
|
2016-01-14 |
2016-05-04 |
山东大学 |
T型钙离子通道抑制剂nnc55-0396在制备抗神经退行性疾病药物中的应用
|
|
WO2017136479A1
(en)
|
2016-02-01 |
2017-08-10 |
Cedars-Sinai Medical Center |
Systems and methods for growth of intestinal cells in microfluidic devices
|
|
US10759806B2
(en)
|
2016-03-17 |
2020-09-01 |
Infinity Pharmaceuticals, Inc. |
Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
|
|
CA3018745A1
(en)
*
|
2016-03-25 |
2017-09-28 |
Genzyme Corporation |
Biomarkers of proteopathies and uses thereof
|
|
WO2017176962A1
(en)
*
|
2016-04-06 |
2017-10-12 |
Lysosomal Therapeutics, Inc. |
Pyrrolo[1,2-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
|
|
WO2017176960A1
(en)
*
|
2016-04-06 |
2017-10-12 |
Lysosomal Therapeutics Inc. |
Pyrazolo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
|
|
JP7046827B2
(ja)
|
2016-04-06 |
2022-04-04 |
リソソーマル・セラピューティクス・インコーポレイテッド |
イミダゾ［１，５－ａ］ピリミジニルカルボキサミド化合物および医学的障害の処置におけるその使用
|
|
US11345698B2
(en)
|
2016-05-05 |
2022-05-31 |
Bial—R&D Investments, S.A. |
Substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-a]pyrazines, related compounds, and their use in the treatment of medical disorders
|
|
BR112018072552A8
(pt)
|
2016-05-05 |
2023-03-14 |
Lysosomal Therapeutics Inc |
Compostos de imidazo [1,2-b]piridazinas e imidazo [1,5-b] piridazinas substituídas, composição farmacêutica que os compreende e seu uso no tratamento de distúrbios médicos
|
|
US10919914B2
(en)
|
2016-06-08 |
2021-02-16 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
|
EP3318277A1
(en)
*
|
2016-11-04 |
2018-05-09 |
Institut du Cerveau et de la Moelle Epiniere-ICM |
Inhibitors of glucosylceramide synthase for the treatment of motor neuron diseases
|
|
WO2018090054A1
(en)
*
|
2016-11-14 |
2018-05-17 |
Berg Llc |
Methods for treating parkinson's disease
|
|
ES2834484T3
(es)
|
2016-11-21 |
2021-06-17 |
Univ Ruhr Bochum |
Método para la preselección de fármacos para enfermedades de plegamiento incorrecto de proteínas
|
|
US11174242B2
(en)
|
2016-12-29 |
2021-11-16 |
Minoryx Therapeutics S.L. |
Heteroaryl compounds and their use
|
|
WO2018140647A1
(en)
|
2017-01-25 |
2018-08-02 |
Cedars-Sinai Medical Center |
In vitro induction of mammary-like differentiation from human pluripotent stem cells
|
|
US11767513B2
(en)
|
2017-03-14 |
2023-09-26 |
Cedars-Sinai Medical Center |
Neuromuscular junction
|
|
WO2018176001A2
(en)
|
2017-03-24 |
2018-09-27 |
Cedars-Sinai Medical Center |
Methods and compositions for production of fallopian tube epithelium
|
|
BR112020001970A2
(pt)
|
2017-08-02 |
2020-08-04 |
Stressmarq Biosciences Inc. |
anticorpo que se liga à alfa-sinucleína ativa
|
|
FI3678739T3
(fi)
*
|
2017-09-07 |
2024-05-21 |
Childrens Hospital Philadelphia |
Koostumuksia ja menetelmiä periytyvän kystatiini c -amyloidiangiopatian (hccaa) ja muiden poikkeaviin amyloidikertymiin liittyvien hermostoa rappeuttavien häiriöiden hoitoon
|
|
CA3076369A1
(en)
|
2017-10-02 |
2019-04-11 |
Denali Therapeutics Inc. |
Fusion proteins comprising enzyme replacement therapy enzymes
|
|
US11247987B2
(en)
|
2017-10-06 |
2022-02-15 |
Forma Therapeutics, Inc. |
Inhibiting ubiquitin specific peptidase 30
|
|
US20190240298A1
(en)
*
|
2018-02-02 |
2019-08-08 |
Enzyvant Farber Gmbh |
Methods for treating farber disease
|
|
EP3768823A4
(en)
|
2018-03-23 |
2022-03-09 |
Cedars-Sinai Medical Center |
METHOD OF USING ISLET CELLS
|
|
US11981918B2
(en)
|
2018-04-06 |
2024-05-14 |
Cedars-Sinai Medical Center |
Differentiation technique to generate dopaminergic neurons from induced pluripotent stem cells
|
|
US12241085B2
(en)
|
2018-04-06 |
2025-03-04 |
Cedars-Sinai Medical Center |
Human pluripotent stem cell derived neurodegenerative disease models on a microfluidic chip
|
|
BR112020020836A2
(pt)
|
2018-04-13 |
2021-01-19 |
University Of Massachusetts |
Vetores de aav bicistrônicos codificando subunidades alfa e beta de hexosaminidase e usos dos mesmos
|
|
JP7543143B2
(ja)
*
|
2018-04-30 |
2024-09-02 |
シーダーズ－サイナイ メディカル センター |
早期発症型孤発性パーキンソン病の分子シグネチャの診断及び薬物スクリーニング
|
|
ES2988920T3
(es)
|
2018-05-17 |
2024-11-22 |
Forma Therapeutics Inc |
Compuestos bicíclicos fusionados útiles como inhibidores de la peptidasa 30 específica de ubiquitina
|
|
SG11202012150UA
(en)
*
|
2018-06-08 |
2021-01-28 |
Ac Immune Sa |
Novel compounds for diagnosis
|
|
WO2020023390A1
(en)
|
2018-07-25 |
2020-01-30 |
Modernatx, Inc. |
Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders
|
|
US12448629B2
(en)
|
2018-10-05 |
2025-10-21 |
University Of Massachusetts |
rAAV vectors for the treatment of GM1 and GM2 gangliosidosis
|
|
MX2021002981A
(es)
|
2018-10-05 |
2021-05-14 |
Forma Therapeutics Inc |
Pirrolinas fusionadas que actuan como inhibidores de la proteasa 30 especifica de la ubiquitina (usp30).
|
|
EP3891500A4
(en)
|
2018-12-05 |
2022-08-31 |
Washington University |
METHODS OF DETECTION, PREVENTION, REVERSAL AND TREATMENT OF NEUROLOGICAL DISEASES
|
|
EP3908611A4
(en)
*
|
2019-01-08 |
2022-10-12 |
Armagen, Inc. |
Methods and compositions for increasing galactosidase beta-1 activity in the cns
|
|
CN113710249A
(zh)
*
|
2019-02-04 |
2021-11-26 |
建新公司 |
用于治疗溶酶体贮积症相关的症状和病症的方法
|
|
EP3920921A4
(en)
*
|
2019-02-07 |
2022-11-02 |
Alsatech, Inc. |
POLYVALENT EMOXYPIN DERIVATIVES
|
|
US20220152165A1
(en)
*
|
2019-03-22 |
2022-05-19 |
Rush University Medical Center |
Combination of nasal gene delivery and oral cinnamic acid, oleamide or gemfibrozil for lysosomal stoarge disorders
|
|
JP2022531177A
(ja)
*
|
2019-04-29 |
2022-07-06 |
トーマス・ジェファーソン・ユニバーシティ |
神経変性障害を治療するための方法
|
|
WO2020257736A1
(en)
|
2019-06-21 |
2020-12-24 |
The Broad Institute, Inc. |
Agents for reversing toxic proteinopathies
|
|
WO2020264531A1
(en)
*
|
2019-06-28 |
2020-12-30 |
The Trustees Of The University Of Pennsylvania |
Intranasal dantrolene administration for treatment of alzheimer's disease
|
|
EP4005638A4
(en)
*
|
2019-07-29 |
2023-07-05 |
Takeda Pharmaceutical Company Limited |
HETEROCYCLIC COMPOUND
|
|
CN110579457B
(zh)
*
|
2019-09-20 |
2021-11-02 |
郑州大学第一附属医院 |
波形蛋白特异响应性荧光探针及其制备方法和应用
|
|
CA3165710A1
(en)
*
|
2020-01-23 |
2021-07-29 |
Retispec Inc. |
Systems and methods for disease diagnosis
|
|
IL295255A
(en)
|
2020-02-03 |
2022-10-01 |
Genzyme Corp |
Methods for treating neurological symptoms associated with lysosomal storage diseases
|
|
KR20230020946A
(ko)
*
|
2020-03-31 |
2023-02-13 |
누오-베타 파마슈티컬 테크놀로지 (상하이) 씨오., 엘티디. |
중수소화 옥소페닐아르신 화합물 및 이의 용도
|
|
CN113720812A
(zh)
*
|
2020-05-26 |
2021-11-30 |
重庆福莱鲨生物技术有限公司 |
一种测定蛋白溶解度的方法
|
|
MX2023001014A
(es)
|
2020-07-24 |
2023-03-01 |
Genzyme Corp |
Composiciones farmaceuticas que comprenden venglustat.
|
|
EP4247792A1
(en)
|
2020-11-19 |
2023-09-27 |
Zevra Denmark A/S |
Processes for preparing arimoclomol citrate and intermediates thereof
|
|
US20240148722A1
(en)
*
|
2021-02-20 |
2024-05-09 |
Biohaven Therapeutics Ltd. |
Small molecules that bind to tdp-43 for the treatment of als and related disorders
|
|
CN113332267A
(zh)
*
|
2021-03-31 |
2021-09-03 |
中山大学孙逸仙纪念医院 |
苯丁酸钠在制备预防或治疗帕金森病的药物中的应用
|
|
WO2022255893A1
(en)
*
|
2021-06-02 |
2022-12-08 |
Qatar Foundation For Education, Science And Community Development |
Methods for diagnosing and differentiating synucleinopathies
|
|
CA3232577A1
(en)
*
|
2021-09-20 |
2023-03-23 |
Alexander SHTILBANS |
Combination therapy for neurodegenerative diseases
|
|
CN116392490A
(zh)
*
|
2021-12-27 |
2023-07-07 |
中国科学院广州生物医药与健康研究院 |
氟桂利嗪的用途以及控制细胞内线粒体数量的方法
|
|
CN119236096A
(zh)
*
|
2024-10-11 |
2025-01-03 |
苏州大学 |
Grp94蛋白作为递药靶点在帕金森病药物载体构建中的应用
|